A 7-year-old boy was diagnosed with RUNX1-RUNX1T1-positive acute myeloid leukemia (AML). Leukemic blasts were morphologically typical of AML-M2, with MPO-positive granules and Auer rods (Fig. 1a). Some leukemic blasts had MPO-negative vacuoles (Fig. 1b). G-banding revealed a karyotype of 46, XY, t(8;21)(q22;q22). Fluorescence in situ hybridization (FISH) analysis revealed a RUNX1-RUNX1T1 fusion signal in 81% of analyzed cells. Molecular complete remission (CR) was achieved after one course of induction therapy, and the patient received six courses of chemotherapy in total.
Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.